HEALWELL AI acquires majority share of Mutuo

TORONTO – HEALWELL AI Inc., a healthcare artificial intelligence company focused on preventative care, is pleased to announce that it has acquired a 51% majority controlling interest in Mutuo Health Solutions, for $5.5 million in cash and shares of HEALWELL.

Mutuo is a medical technology company specializing in AI-powered ambient scribe solutions for clinical documentation whose flagship product, the AutoScribe platform, transcribes clinician-patient dialogue into structured electronic medical records (EMR) data in real-time using machine learning (ML) and natural language processing (NLP).

Dr. Noah Crampton (pictured), CEO of Mutuo Health Solutions, commented, “Our team at Mutuo is thrilled to join forces with HEALWELL to bring AutoScribe to more healthcare providers across Canada and beyond. This partnership allows us to leverage HEALWELL’s expertise and vast network to accelerate our mission of reducing administrative fatigue for doctors while improving the quality of care that patients receive. We are eager to see the positive impact this collaboration will have on the healthcare community.”

This acquisition is aligned with HEALWELL’s strategy to acquire and enhance AI-enabled healthcare technologies that improve clinical efficiency, patient outcomes and ultimately assist with early disease detection.

Founded in 2018 by a team of AI researchers and healthcare professionals, including a family doctor who experienced first-hand the challenges of documentation burnout, Mutuo’s commercializing of AutoScribe was initiated as part of a unique collaboration between the University of Toronto and Unity Health Toronto.

The platform sets itself apart with its focus on precision, security, and integration within Canadian healthcare, making every patient interaction an opportunity to optimize care. By capturing and structuring patient data in real time, AutoScribe enables healthcare providers to focus on patient care, enhancing clinical accuracy and operational efficiency.

Mutuo’s AutoScribe platform transcends traditional medical dictation, the company said, by utilizing advanced AI-driven transcription and predictive capabilities, continuously improving through its machine learning framework.

HEALWELL’s acquisition of a controlling stake in Mutuo will deepen the company’s technology portfolio and expand its offering of AI-driven healthcare solutions.

HEALWELL plans to integrate AutoScribe into its proprietary best-in-class AI-enabled clinical decision support co-pilots; creating a next generation suite of physician co-pilots that will provide highly integrated best-in-class clinical administration automation and clinical decision support.

By integrating AutoScribe’s capabilities, HEALWELL will be able to provide advanced, customizable digital assistance to healthcare providers, particularly addressing the growing need for documentation and electronic medical record (EMR) automation in clinics and hospitals.

The acquisition helps to further position HEALWELL as a leader in predictive AI solutions designed to streamline clinical workflows, improve patient care, and assist providers with advanced clinical decision support.

Dr. Alexander Dobranowski, CEO of HEALWELL, commented, “We are excited to welcome Mutuo and their remarkable AutoScribe technology to HEALWELL. This acquisition is another step forward in our mission to provide healthcare professionals with the most advanced AI tools to optimize patient care and ultimately help with the earlier identification and detection of disease. AutoScribe’s unique real-time transcription capabilities, combined with its predictive AI framework, will significantly enhance how clinicians manage patient data, allowing them to focus more on patient-centered care. We look forward to working with Mutuo’s team of talented researchers and medical professionals to further scale this technology.”

About HEALWELL AI
HEALWELL is a healthcare artificial intelligence company focused on preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. To learn more about HEALWELL, please visit https://healwell.ai/